Loading
  • Slide

    A XENOTHERAPY PLATFORM WITH EMBEDDED TECHNOLOGY

    THAT RENOVATES IMMUNOLOGICAL TREATMENTS

  • Slide

    A XENOTHERAPY PLATFORM WITH EMBEDDED TECHNOLOGY

    THAT RENOVATES IMMUNOLOGICAL TREATMENTS

EXPERTISE

Innovative immunotherapy

Project Name

XENOTHERA's plateform for creation of hyperimmune polyclonal sera is based on the following patented process:

  • Define the proper animal and its genetic background for engineering
  • Choose and optimize the immunogen
  • Turn the animal's immune response for an optimized therapeutic efficiency
  • Purify the immunoglobulins of interest
  • Lead a translational development program
  • Product and commercialize

Therapeutic domains:

  • Immunology
  • Oncology
  • Infectious diseases
  • Others

PARTNERSHIPS

Xenothera is built on a worldwide network of scientific partners

Centre Hospitalier Universitaire de Nantes
Inserm
Oniris
Universita degli Studi di Padova

OUR TEAM

Seasonned entrepreneurs with demonstrated pas successes

Odile Duvaux

ODILE DUVAUX

CEO
M.D., Ph. D., formerly main partner in a consultant firm specialized in strategy: DMJ Consultants
Jean-Paul Soulillou

JEAN-PAUL SOULILLOU

CSO
Emeritus Professor of Medicine, worldwide renowned immunologist Numerous scientific publications
Emanuele Cozzi

EMANUELE COZZI

Chairman of the Scientific Advisory Board
MD, Professor of Immunology at the University of Padua, former president of the International Xenotransplantation Association
Jean-Marie Bach

JEAN-MARIE BACH

Scientific advisor
DMV, Ph.D., Professor at Oniris, Veterinary school of Nantes
Cesare Galli

CESARE GALLI

Genetic engineering
D.M.V., Ph.D., founder of the company Avantea (Cremona, Italy), worldwide renowned animal genetic engineer
Marc Bouillet

MARC BOUILLET

Scientific advisor
M.D., former partner in several pharmaceutical companies and CEO of several patient associations
Executives:
Odile Duvaux
Jean-Paul Soulillou
Scientific advisors:
Emanuele Cozzi
Jean-Marie Bach
Cesare Galli
Marc Bouillet

ABOUT US

An agile company with a fast-paced development

XENOTHERA is a biotechnologies company at the top of innovation, which creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases.

Our technological platform is built on a double expertise of animal genetics and mastery of immunology processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera.

XENOTHERA’s platform ensures short-time development thanks to our mastery of the entire process, from animal genetics, choice of the immunogen, selection and purification of interesting immunoglobulins, and access to market authorization in accelerated timescale.

PROOF OF CONCEPT

SERIE A FUNDRAISING

IND

PHASE I

CONTACT INFORMATION

To contact us, use the form or see our full contact below.

  • Faculté de Médecine de Nantes
    1 rue Gaston Veil - 44035 Nantes Cedex 1 - France
  • +33 240412987
  • +33 612192724
  • contact@xenothera.com